Zerlasiran is under clinical development by Silence Therapeutics and currently in Phase II for Atherosclerosis. According to GlobalData, Phase II drugs for Atherosclerosis have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zerlasiran’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zerlasiran overview
SLN-360 is under development for the treatment of atherosclerotic cardiovascular disease events associated with high Lp(a) levels. The drug candidate is a siRNA oligonucleotide which is conjugated with N-Acetylgalactosamine (GalNAc), derivative of galactose. It is administered subcutaneously and acts by targeting apolipoprotein A. It is based on mRNAi GOLD platform.
Silence Therapeutics overview
Silence Therapeutics is a developer of therapeutics that channels gene silencing to cure life-threatening diseases. The company’s pipeline products include SLN124 and SLN360. Its SLN360 is developed for the treatment of cardiovascular disease with high Lp(a) in risk of heart disease and heart stroke, and SLN124 for e-Thalassaemia and myelodysplastic syndrome. Silence Therapeutics also provides RNA interfaces that include short interfering RNA (siRNA) and messenger RNAs (mRNA). The company collaborates with pharmaceutical, biotechnology companies and academic research institutions. It operates in Germany, the US and the UK. Silence Therapeutics is headquartered in London, England, the UK.
For a complete picture of Zerlasiran’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
